Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2015—BBCS received 510(k) clearance for its ABO Wheels, a blood bank software solution that is part of the company’s ABO Suite. ABO Wheels is a mobile blood-collection application that allows blood centers to conduct paperless donor registration and screening at either a collection facility or a non-fixed site, regardless of connectivity to the main database.
March 2015—The CE-IVD Oncomine Solid Tumor DNA kit from Thermo Fisher Scientific enables accurate and reliable multiplexed sequencing of formalin-fixed, paraffin-embedded tumor. Based on the Ion Torrent AmpliSeq technology, the kit allows detection of single nucleotide somatic changes, inversions, insertions, and deletions using as little as 10 ng of FFPE DNA …
March 2015—The Compass Group has awarded Visiun a sole-source agreement for business intelligence software for Compass Group’s 26 nonprofit health systems.
March 2015—Transworld Systems, a cash-flow management and profit recovery company, announced a dedicated division to work with medical laboratories. Profit Recovery and Profit Recovery Plus are flat-fee, automated collection systems that generate diplomatic, written demands from a third party. According to the company, flat-fee written contacts are getting outstanding results in the low-balance, high-volume environment laboratories create. The initiative is headed by Michael Paro, accounts receivable advisory specialist for medical labs.
March 2014—The Food and Drug Administration cleared a screening test that predicts a patient’s risk of future coronary heart disease events, such as heart attacks. The test is cleared for use in all adults with no history of heart disease, but studies submitted by the company and reviewed by the FDA show that the test is better at discerning this risk in women, particularly black women.
March 2014—The BioFlo 320 from Eppendorf is built with integrated control for both autoclavable and single-use vessels with a total working volume of 250 mL to 40 L on a single control platform. Ethernet communication connects up to eight systems from a single user interface for multi-unit control, and the Mettler-Toledo Intelligent Sensor Management platform is built into the system.
March 2014—The Clinical and Laboratory Standards Institute has published a new document, “Planning for Laboratory Operations During a Disaster; Approved Guideline (GP36-A).” The document provides guidance for laboratory and health care leadership for development, implementation, and sustainment of effective emergency preparedness plans (all hazards) supporting nonanalytical components of clinical and public health laboratory services that may pertain to various natural and manmade disasters.
March 2014—The Ativa microlab from Ativa Medical is a point-of-care device designed to perform the most common blood-based tests in a clinical setting in five minutes. The system requires only a few drops of blood and runs on a disposable microfluidic card.
March 2014—The Diagnostics Division of Siemens Healthcare is unveiling its latest point-of-care acute care analyzer for the management of patients with cardiovascular disease symptoms. The company’s Stratus CS 200 Acute Care Diagnostic System is designed for simple operation and instrument management at the point of care to help facilitate rapid decision-making and provide optimal patient care.
March 2014—Quest Diagnostics will collaborate with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis, and treatment for four strains of viral hepatitis in the U.S. Under terms of the multiyear contract, Quest will provide CDC researchers with analytics expertise and access to the company’s national Health Trends database of de-identified clinical testing hepatitis data.
